Pabst, Thomas

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006

2017

Gorin, Norbert-Claude; Labopin, Myriam; Czerw, Tomasz; Pabst, Thomas; Blaise, Didier; Dumas, Pierre-Yves; Nemet, Damir; Arcese, William; Trisolini, Silvia Maria; Wu, Depei; Huynh, Anne; Zuckerman, Tsila; Meijer, Ellen; Cagirgan, Seckin; Cornelissen, Jan; Houhou, Mohamed; Polge, Emmanuelle; Mohty, Mohamad; Nagler, Arnon (2017). Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer, 123(5), pp. 824-831. John Wiley & Sons 10.1002/cncr.30400

2016

Riether, Carsten; Schürch, Christian M.; Bührer, Elias D.; Hinterbrandner, Magdalena; Huguenin, Anne-Laure; Höpner, Sabine; Zlobec, Inti; Pabst, Thomas; Radpour, Ramin; Ochsenbein, Adrian F. (2016). CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. The Journal of experimental medicine, 214(2), pp. 359-380. Rockefeller Univ. Press 10.1084/jem.20152008

Meissner, J; Finel, H; Dietrich, S; Boumendil, A; Kanfer, E; Laboure, G; Abecasis, M; Cornelissen, J; Delage, J; Finke, J; Hess, U; Ludwig, H; Mohty, M; Pabst, Thomas; Pioltelli, P; Robinson, S; Samaras, P; Montoto, S; Dreger, P (2016). Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. (In Press). Bone marrow transplantation Nature Publishing Group 10.1038/bmt.2016.339

Heini, Alexander D; Berger, Martin Dave; Seipel, Katja; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz, Yara; Novak, Urban; Pabst, Thomas (2016). Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years. Leukemia research, 53, pp. 28-34. Elsevier 10.1016/j.leukres.2016.12.001

Gössi, F; Spahn, Martin; Zweifel, Martin; Panagiotis, S; Mischo, A; Stenner, F; Hess, U; Berthold, D; Bargetzi, M; Schardt, Julian; Pabst, Thomas (2016). Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. Bone marrow transplantation, 52(2), pp. 334-336. Nature Publishing Group 10.1038/bmt.2016.285

Stettler, Jasmin; Novak, Urban; Baerlocher, Gabriela M.; Seipel, Katja; Mansouri Taleghani, Behrouz; Pabst, Thomas (2016). Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy. Leukemia & lymphoma, 58(5), pp. 1076-1083. Informa Healthcare 10.1080/10428194.2016.1233542

Fridle, Chantal; Medinger, Michael; Wilk, Matthias C; Seipel, Katja; Passweg, Jakob; Manz, Markus G; Pabst, Thomas (2016). Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML). Leukemia & lymphoma, 58(5), pp. 1068-1075. Informa Healthcare 10.1080/10428194.2016.1235274

Voegeli, Michèle; Rondeau, Stephanie; Berardi Vilei, Simona; Lerch, Erika; Wannesson, Luciano; Pabst, Thomas; Rentschler, Jochen; Bargetzi, Mario; Jost, Lorenz; Ketterer, Nicolas; Bischof Delaloye, Angelika; Ghielmini, Michele (2016). Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). (In Press). Hematological oncology Wiley 10.1002/hon.2348

Versluis, J; In 't Hout, F E M; Devillier, R; van Putten, W L J; Manz, M G; Vekemans, M-C; Legdeur, M-C; Passweg, J R; Maertens, J; Kuball, J; Biemond, B J; Valk, P J M; van der Reijden, B A; Meloni, G; Schouten, H C; Vellenga, E; Pabst, Thomas; Willemze, R; Löwenberg, B; Ossenkoppele, G; ... (2016). Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 31(1), pp. 26-33. Nature Publishing Group 10.1038/leu.2016.183

Steinrücken, Julia; Pabst, Thomas; Zimmerli, Stefan; Marschall, Jonas (2016). Low impact of urine cultures as a diagnostic tool in patients with neutropenic fever. Infectious diseases, 48(11-12), pp. 1-3. Taylor & Francis 10.1080/23744235.2016.1205216

Hitz, Felicitas; Zucca, Emanuele; Pabst, Thomas; Fischer, Natalie; Cairoli, Anne; Samaras, Panagiotis; Caspar, Clemens B; Mach, Nicolas; Krasniqi, Fatime; Schmidt, Adrian; Rothermundt, Christian; Enoiu, Milica; Eckhardt, Katrin; Berardi Vilei, Simona; Rondeau, Stephanie; Mey, Ulrich (2016). Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. British journal of haematology, 174(2), pp. 255-263. Wiley-Blackwell 10.1111/bjh.14049

Berger, Martin D; Heini, Alexander D; Seipel, Katja; Mueller, Beatrice; Angelillo-Scherrer, Anne; Pabst, Thomas (2016). Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia (In Press). Hematological oncology Wiley 10.1002/hon.2307

Taverna, Christian; Martinelli, Giovanni; Hitz, Felicitas; Mingrone, Walter; Pabst, Thomas; Cevreska, Lidija; Del Giglio, Auro; Vanazzi, Anna; Laszlo, Daniele; Raats, Johann; Rauch, Daniel; Vorobiof, Daniel A; Lohri, Andreas; Biaggi Rudolf, Christine; Rondeau, Stéphanie; Rusterholz, Corinne; Heijnen, Ingmar A F M; Zucca, Emanuele; Ghielmini, Michele (2016). Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. Journal of clinical oncology, 34(5), pp. 495-500. American Society of Clinical Oncology 10.1200/JCO.2015.61.3968

Seipel, Katja; Marques, Miguel Teixera; Bozzini, Marie-Ange; Meinken, Christina; Mueller, Beatrice U; Pabst, Thomas (2016). Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia. Clinical cancer research, 22(3), pp. 746-756. Association for Cancer Research 10.1158/1078-0432.CCR-15-1054

Berger, Martin Dave; Branger, Giacomo; Klaeser, Bernd; Mansouri Taleghani, Behrouz; Novak, Urban; Banz Wälti, Yara; Müller, Beatrice Ursula; Pabst, Thomas (2016). Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma. Hematological oncology, 34(3), pp. 133-139. Wiley 10.1002/hon.2197

Pathak, Anand; Seipel, Katja; Pemov, Alexander; Dewan, Ramita; Brown, Christina; Ravichandran, Sarangan; Luke, Brian T; Malasky, Michael; Suman, Shalabh; Yeager, Meredith; Cancer GenomicsResearch Laboratory, Nci Dceg; Cancer Sequencing Working Group, Nci Dceg; Parry, Dilys M; Gatti, Richard A; Caporaso, Neil E; Mulvihill, John; Goldin, Lynn R; Pabst, Thomas; McMaster, Mary L and Stewart, Douglas R (2016). Whole-exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow-up of a large family. Haematologica - the hematology journal, 101(7), pp. 846-852. Ferrata-Storti Foundation 10.3324/haematol.2015.130799

Driessen, Christoph; Kraus, Marianne; Joerger, Markus; Rosing, Hilde; Bader, Jürgen; Hitz, Felicitas; Berset, Catherine; Xyrafas, Alexandros; Hawle, Hanne; Berthod, Gregoire; Overkleeft, Hermann S; Sessa, Cristiana; Huitema, Alwin; Pabst, Thomas; von Moos, Roger; Hess, Dagmar; Mey, Ulrich J M (2016). Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica - the hematology journal, 101(3), pp. 346-355. Ferrata-Storti Foundation 10.3324/haematol.2015.135780

2015

Mueller, Beatrice U; Keller, Sandra; Seipel, Katja; Mansouri Taleghani, Behrouz; Rauch, Daniel; Betticher, Daniel; Egger, Thomas; Pabst, Thomas (2015). Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity. Leukemia & lymphoma, 57(5), pp. 1122-1129. Informa Healthcare 10.3109/10428194.2015.1079315

Versluis, Jurjen; Hazenberg, Carin L E; Passweg, Jakob R; van Putten, Wim L J; Maertens, Johan; Biemond, Bart J; Theobald, Matthias; Graux, Carlos; Kuball, Jurgen; Schouten, Harry C; Pabst, Thomas; Löwenberg, Bob; Ossenkoppele, Gert; Vellenga, Edo; Cornelissen, Jan J (2015). Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. The Lancet. Haematology, 2(10), e427-e436. Elsevier 10.1016/S2352-3026(15)00148-9

Walter, Roland B; Othus, Megan; Löwenberg, Bob; Ossenkoppele, Gert J; Petersdorf, Stephen H; Pabst, Thomas; Vekemans, Marie-Christiane; Appelbaum, Frederick R; Erba, Harry P; Estey, Elihu H (2015). Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. Haematologica - the hematology journal, 100(10), e409-e411. Ferrata-Storti Foundation 10.3324/haematol.2015.130013

Tawana, Kiran; Wang, Jun; Renneville, Aline; Bödör, Csaba; Hills, Robert; Loveday, Chey; Savic, Aleksandar; Van Delft, Frederik W; Treleaven, Jennifer; Georgiades, Panayiotis; Uglow, Elizabeth; Asou, Norio; Uike, Naokuni; Debeljak, Maruša; Jazbec, Janez; Ancliff, Philip; Gale, Rosemary; Thomas, Xavier; Mialou, Valerie; Döhner, Konstanze; ... (2015). Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood, 126(10), pp. 1214-1223. American Society of Hematology 10.1182/blood-2015-05-647172

Schardt, Julian; Keller, Manuela; Seipel, Katja; Pabst, Thomas (2015). Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene. Biochimica et biophysica acta, 1849(9), pp. 1188-1197. Elsevier 10.1016/j.bbagrm.2015.07.003

Mamot, Christoph; Klingbiel, Dirk; Hitz, Felicitas; Renner, Christoph; Pabst, Thomas; Driessen, Christoph; Mey, Ulrich; Pless, Miklos; Bargetzi, Mario; Krasniqi, Fatime; Gigli, Federica; Hany, Thomas; Samarin, Andrei; Biaggi, Christine; Rusterholz, Corinne; Dirnhofer, Stephan; Zucca, Emanuele; Martinelli, Giovanni (2015). Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Journal of clinical oncology, 33(23), pp. 2523-2529. American Society of Clinical Oncology 10.1200/JCO.2014.58.9846

Keller, Sandra; Seipel, Katja; Novak, Urban; Mueller, Beatrice U; Mansouri Taleghani, Behrouz; Leibundgut, Kurt; Pabst, Thomas (2015). Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Leukemia research, 39(7), pp. 786-792. Elsevier 10.1016/j.leukres.2015.03.015

Berger, Martin Dave; Branger, Giacomo; Leibundgut, Kurt; Baerlocher, Gabriela M; Seipel, Katja; Mueller, Beatrice U; Gregor, Michael; Ruefer, Axel; Pabst, Thomas (2015). CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma. Leukemia research, 39(6), pp. 561-567. Elsevier 10.1016/j.leukres.2015.03.004

Kamber, C; Zimmerli, Stefan; Suter, Franziska Marta; Müller, Beatrice Ursula; Mansouri Taleghani, Behrouz; Betticher, Daniel; Zander, T; Pabst, Thomas (2015). Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone marrow transplantation, 50(4), pp. 573-578. Nature Publishing Group 10.1038/bmt.2014.290

Wetzel, Dana; Müller, Beatrice Ursula; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Seipel, Katja; Leibundgut, Kurt; Pabst, Thomas (2015). Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia. British journal of haematology, 168(2), pp. 268-273. Wiley-Blackwell 10.1111/bjh.13118

Koechli, Valentin; Klaeser, Bernd; Banz Wälti, Yara; Müller, Beatrice Ursula; Pabst, Thomas (2015). Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma. Leukemia research, 39(3), pp. 307-310. Elsevier 10.1016/j.leukres.2014.12.016

Cornelissen, J J; Versluis, J; Passweg, Jakob; van Putten, W L J; Manz, M G; Maertens, J; Beverloo, H B; Valk, P J M; van Marwijk Kooy, M; Wijermans, P W; Schaafsma, M R; Biemond, B J; Vekemans, M-C; Breems, D A; Verdonck, L F; Fey, Martin; Jongen-Lavrencic, M; Janssen, J J W M; Huls, G; Kuball, J; ... (2015). Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia, 29(5), pp. 1041-1050. Nature Publishing Group 10.1038/leu.2014.332

Garg, Abhishek D; Galluzzi, Lorenzo; Apetoh, Lionel; Baert, Thais; Birge, Raymond B; Bravo-San Pedro, José Manuel; Breckpot, Karine; Brough, David; Chaurio, Ricardo; Cirone, Mara; Coosemans, An; Coulie, Pierre G; De Ruysscher, Dirk; Dini, Luciana; de Witte, Peter; Dudek-Peric, Aleksandra M; Faggioni, Alberto; Fucikova, Jitka; Gaipl, Udo S; Golab, Jakub; ... (2015). Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in immunology, 6(588), p. 588. Frontiers Research Foundation 10.3389/fimmu.2015.00588

Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Duchosal, Michel A; Heim, Dominik; Hess, Urs; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Taverna, Christian; Zander, Thilo; Renner, Christoph (2015). Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 145, w14100. EMH Schweizerischer Ärzteverlag 10.4414/smw.2015.14100

2014

Voermans, Nicol C; Benveniste, Olivier; Minnema, Monique C; Lokhorst, Henk; Lammens, Martin; Meersseman, Wouter; Delforge, Michel; Kuntzer, Thierry; Novy, Jan; Pabst, Thomas; Bouhour, Françoise; Romero, Norma; Leblond, Veronique; Bergh, Peter van den; Vekemans, Marie-Christiane; Engelen, Baziel G van; Eymard, Bruno (2014). Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCT. Neurology, 83(23), pp. 2133-2139. Lippincott Williams & Wilkins 10.1212/WNL.0000000000001047

Morris, Curly; de Wreede, Liesbeth; Scholten, Marijke; Brand, Ronald; van Biezen, Anja; Sureda, Anna; Dickmeiss, Ebbe; Trneny, Marek; Apperley, Jane; Chiusolo, Patrizia; van Imhoff, Gustaaf W; Lenhoff, Stig; Martinelli, Giovanni; Hentrich, Marcus; Pabst, Thomas; Onida, Francesco; Quinn, Michael; Kroger, Nicolaus; de Witte, Theo and Ruutu, Tapani (2014). Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion, 54(10), pp. 2514-2522. Wiley-Blackwell 10.1111/trf.12759

Walter, R B; Othus, M; Burnett, A K; Löwenberg, B; Kantarjian, H M; Ossenkoppele, G J; Hills, R K; Ravandi, F; Pabst, Thomas; Evans, A; Pierce, S R; Vekemans, M-C; Appelbaum, F R; Estey, E H (2014). Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia, 29(2), pp. 312-320. Nature Publishing Group 10.1038/leu.2014.242

Terwijn, Monique; Zeijlemaker, Wendelien; Kelder, Angèle; Rutten, Arjo P; Snel, Alexander N; Scholten, Willemijn J; Pabst, Thomas; Verhoef, Gregor; Löwenberg, Bob; Zweegman, Sonja; Ossenkoppele, Gert J; Schuurhuis, Gerrit J (2014). Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS ONE, 9(9), e107587. Public Library of Science 10.1371/journal.pone.0107587

Schmid, Andrea; Friess, Dorothea; Mansouri Taleghani, Behrouz; Keller, Peter; Müller, Beatrice Ursula; Baerlocher, Gabriela M.; Leibundgut, Kurt; Pabst, Thomas (2014). Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leukemia & lymphoma, 56(3), pp. 608-614. Informa Healthcare 10.3109/10428194.2014.927454

Jegerlehner, Sabrina; Rothenbühler, Simon Paul; Pabst, Thomas (2014). Vision impairment at diagnosis of cancer - choroidal metastasis. Praxis - schweizerische Rundschau für Medizin, 103(11), pp. 641-647. Huber 10.1024/1661-8157/a001671

Funke, Manuela; Schäfer, Stephan; Pabst, Thomas; Geiser, Thomas; Pachlopnik Schmid, J; Dahinden, Clemens A.; Zimmerli, Stefan (May 2014). Necrotizing mediastinal lymphadenopathy due to disseminated M. abcessus infection revealing MonoMAc Syndrome - a case report (Unpublished). In: Annual Meeting of the Swiss Society for Pneumology. Interlaken. 08.-09.05.2014.

Funke, Manuela; Schäfer, Stephan; Pabst, Thomas; Geiser, Thomas; Pachlopnik Schmid, J; Dahinden, Clemens A.; Zimmerli, Stefan (May 2014). Necrotizing mediastinal lymphadenopathy due to disseminated M. abcessus infection recealing MonoMAc Syndrome - a case report (Unpublished). In: Annual Meeting of the Swiss Society for Pneumology. Interlaken. 08.-09.05.214.

Raschle, Joëlle; Banz Wälti, Yara; Suter, Thomas; Pabst, Thomas (2014). A single-centre cohort of patients with systemic light chain AL-amyloidosis treated with conventional chemotherapy or with high-dose chemotherapy and autologous stem cell transplantation. Swiss medical weekly, 144, w13922. EMH Schweizerischer Ärzteverlag 10.4414/smw.2014.13922

2013

Berger, Martin D.; Banz, Yara; Pabst, Thomas (2013). Pitfalls in the diagnosis of intravascular large B-cell lymphoma. European journal of haematology, 91(6), pp. 563-564. Wiley-Blackwell 10.1111/ejh.12162

Terwijn, M.; van Putten, W. L. J.; Kelder, A.; van der Velden, V. H. J.; Brooimans, R. A.; Pabst, T.; Maertens, J.; Boeckx, N.; de Greef, G. E.; Valk, P. J. M.; Preijers, F. W. M. B.; Huijgens, P. C.; Drager, A. M.; Schanz, U.; Jongen-Lavrecic, M.; Biemond, B. J.; Passweg, J. R.; van Gelder, M.; Wijermans, P.; Graux, C.; ... (2013). High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. Journal of clinical oncology, 31(31), pp. 3889-3897. American Society of Clinical Oncology 10.1200/JCO.2012.45.9628

Gutbrodt, K. L.; Schliemann, C.; Giovannoni, L.; Frey, K.; Pabst, Thomas; Klapper, W.; Berdel, W. E.; Neri, D. (2013). Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia. Science translational medicine, 5(201), 201ra118-201ra118. American Association for the Advancement of Science 10.1126/scitranslmed.3006221

Schlenk, R. F.; Taskesen, E.; van Norden, Y.; Krauter, J.; Ganser, A.; Bullinger, L.; Gaidzik, V. I.; Paschka, P.; Corbacioglu, A.; Gohring, G.; Kundgen, A.; Held, G.; Gotze, K.; Vellenga, E.; Kuball, J.; Schanz, U.; Passweg, J.; Pabst, Thomas; Maertens, J.; Ossenkoppele, G. J.; ... (2013). The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood, 122(9), pp. 1576-1582. American Society of Hematology 10.1182/blood-2013-05-503847

Hitz, F; Fischer, N; Pabst, Th; Caspar, C; Berthod, G; Eckhardt, K; Berardi Vilei, S; Zucca, E; Mey, U; On behalf of Swiss Group for Clinical Cancer Research (SAKK) Be, (2013). Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Annals of hematology, 92(8), pp. 1033-1040. Berlin: Springer 10.1007/s00277-013-1751-z

Passweg, Jakob R.; Pabst, Thomas; Blum, Sabine; Bargetzi, Mario; Li, Qiyu; Heim, Dominik; Stussi, Georg; Gregor, Michael; Leoncini, Leda; Meyer-Monard, Sandrine; Brauchli, Peter; Chalandon, Yves; Swiss Group for Clinical Cancer Research, SAKK (2013). Azacytidine for acute myeloid leukemia in elderly or frail patients: A phase II trial (SAKK 30/07). Leukemia & lymphoma, 55(1), pp. 87-91. London: Informa Healthcare 10.3109/10428194.2013.790540

Passweg, Jakob R; Baldomero, Helen; Bargetzi, Mario; Bucher, Christoph; Chalandon, Yves; Duchosal, Michel A; Gratwohl, Alois; Güngör, Tayfun; Hess, Urs; Leibundgut, Kurt; de Faveri, Grazia Nicoloso; Ozsahin, Hulya; Pabst, Thomas; Renner, Christoph; Stern, Martin; Stussi, Georg; Schanz, Urs; SBST (Swiss Blood Stem Cell Transplantation Group), (2013). Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. Swiss medical weekly, 143, w13757. Muttenz: EMH Schweizerischer Ärzteverlag

Neubauer, Henning; Pabst, Thomas; Dick, Anke; Machann, Wolfram; Evangelista, Laura; Wirth, Clemens; Köstler, Herbert; Hahn, Dietbert; Beer, Meinrad (2013). Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRI. Pediatric radiology, 43(1), pp. 103-14. Berlin: Springer 10.1007/s00247-012-2492-1

Gröschel, Stefan; Schlenk, Richard F; Engelmann, Jan; Rockova, Veronika; Teleanu, Veronica; Kühn, Michael W M; Eiwen, Karina; Erpelinck, Claudia; Havermans, Marije; Lübbert, Michael; Germing, Ulrich; Schmidt-Wolf, Ingo G H; Beverloo, H Berna; Schuurhuis, Gerrit J; Ossenkoppele, Gert J; Schlegelberger, Brigitte; Verdonck, Leo F; Vellenga, Edo; Verhoef, Gregor; Vandenberghe, Peter; ... (2013). Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Journal of clinical oncology, 31(1), pp. 95-103. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.41.5505

Wannesson, Luciano; Bargetzi, Mario; Cairoli, Anne; Cerutti, Alessandra; Heim, Dominik; Hess, Urs; Lerch, Erika; Pabst, Thomas; Renner, Christoph; Samaras, Panagiotis; Zucca, Emanuele (2013). Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leukemia & lymphoma, 54(1), pp. 36-40. London: Informa Healthcare 10.3109/10428194.2012.702903

Bükki, Johannes; Stanga, Zeno; Buitrago Tellez, Firouzeh; Duclos, Kathleen; Kolev, Mirjam; Krähenmann, Peter; Pabst, Thomas; Iff, Samuel; Jüni, Peter (2013). Omega-3 poly-unsaturated fatty acids for the prevention of severe neutropenic enterocolitis in patients with acute myeloid leukemia. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 65(6), pp. 834-842. Routledge 10.1080/01635581.2013.801998

2012

Pabst, Thomas; Vellenga, Edo; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Vekemans, Marie-Christiane; Biemond, Bart; Sonneveld, Peter; Passweg, Jakob; Verdonck, Leo; Legdeur, Marie-Cecile; Theobald, Matthias; Jacky, Emanuel; Bargetzi, Mario; Maertens, Johan; Ossenkoppele, Gert Jan; Löwenberg, Bob (2012). Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose-escalation of cytarabine. Blood, 119(23), pp. 5367-73. Washington, D.C.: American Society of Hematology 10.1182/blood-2011-11-389841

von Grünigen, Isabelle; Raschle, Joëlle; Rüsges-Wolter, Ilka; Taleghani, Behrouz Mansouri; Mueller, Beatrice U; Pabst, Thomas (2012). The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential. Leukemia research, 36(11), pp. 1325-9. Amsterdam: Elsevier 10.1016/j.leukres.2012.05.027

Mans, Sarah; Banz, Yara; Mueller, Beatrice U; Pabst, Thomas (2012). The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients. Blood, 120(13), pp. 2690-9. Washington, D.C.: American Society of Hematology 10.1182/blood-2012-02-412759

Ossenkoppele, Gert J; Stussi, Georg; Maertens, Johan; van Montfort, Kees; Biemond, Bart J; Breems, Dimitri; Ferrant, August; Graux, Carlos; de Greef, Georgine E; Halkes, C J M; Hoogendoorn, Mels; Hollestein, Rene M; Jongen-Lavrencic, Mojca; Levin, Mark D; van de Loosdrecht, Arjan A; van Marwijk Kooij, Marinus; van Norden, Yvette; Pabst, Thomas; Schouten, Harry C; Vellenga, Edo; ... (2012). Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood, 120(24), pp. 4706-11. Washington, D.C.: American Society of Hematology 10.1182/blood-2012-04-420596

Cornelissen, Jan J; Breems, Dimitri; van Putten, Wim L J; Gratwohl, Alois A; Passweg, Jakob R; Pabst, Thomas; Maertens, Johan; Beverloo, H Berna; van Marwijk Kooy, Marinus; Wijermans, Pierre W; Biemond, Bart J; Vellenga, Edo; Verdonck, Leo F; Ossenkoppele, Gert J; Löwenberg, Bob (2012). Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. Journal of clinical oncology, 30(17), pp. 2140-6. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.39.6499

2011

O'Meara, A; Pabst, T; Heim, D; Gerull, S; Bucher, C; Halter, J; Arber, C; Rovò, A; Tichelli, A; Gratwohl, A; Stern, M (2011). High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML. Bone marrow transplantation, 46(5), pp. 636-40. London: Nature Publishing Group 10.1038/bmt.2010.181

Fos, José; Pabst, Thomas; Petkovic, Vibor; Ratschiller, Daniel; Mueller, Beatrice U (2011). Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis. Blood, 117(18), pp. 4881-4. Washington, D.C.: American Society of Hematology 10.1182/blood-2010-11-320747

Patterson, Andrew D; Maurhofer, Olivier; Beyoglu, Diren; Lanz, Christian; Krausz, Kristopher W; Pabst, Thomas; Gonzalez, Frank J; Dufour, Jean-François; Idle, Jeffrey R (2011). Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer research, 71(21), pp. 6590-600. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-11-0885

Raschle, J; Ratschiller, D; Mans, S; Mueller, B U; Pabst, T (2011). High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. British journal of cancer, 105(7), pp. 970-4. Basingstoke: Nature Publishing Group 10.1038/bjc.2011.329

Haefliger, Simon; Klebig, Christiane; Schaubitzer, Kerstin; Schardt, Julian; Timchenko, Nikolai; Mueller, Beatrice U; Pabst, Thomas (2011). Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Blood, 117(22), pp. 5931-40. Washington, D.C.: American Society of Hematology 10.1182/blood-2010-08-304485

Löwenberg, Bob; Pabst, Thomas; Vellenga, Edo; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Biemond, Bart J; Gratwohl, Alois; de Greef, Georgine E; Verdonck, Leo F; Schaafsma, Martijn R; Gregor, Michael; Theobald, Matthias; Schanz, Urs; Maertens, Johan; Ossenkoppele, Gert J; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON, (2011). Cytarabine dose for acute myeloid leukemia. New England journal of medicine NEJM, 364(11), pp. 1027-36. Waltham, Mass.: Massachusetts Medical Society MMS

Schardt, Julian A; Mueller, Beatrice U; Pabst, Thomas (2011). Activation of the unfolded protein response in human acute myeloid leukemia. Methods in enzymology, 489, pp. 227-243. New York, N.Y.: Academic Press 10.1016/B978-0-12-385116-1.00013-3

2010

Eyholzer, Marianne; Schmid, Sabine; Schardt, Julian A; Haefliger, Simon; Mueller, Beatrice U; Pabst, Thomas (2010). Complexity of miR-223 regulation by CEBPA in human AML. Leukemia research, 34(5), pp. 672-6. Amsterdam: Elsevier 10.1016/j.leukres.2009.11.019

Bonadies, Nicola; Pabst, Thomas; Mueller, Beatrice U (2010). Heterozygous deletion of the PU.1 locus in human AML. Blood, 115(2), pp. 331-4. Washington, D.C.: American Society of Hematology 10.1182/blood-2009-03-212225

Schardt, Julian A; Eyholzer, Marianne; Timchenko, Nikolai A; Mueller, Beatrice U; Pabst, Thomas (2010). Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine, 14(6B), pp. 1509-0519. Bucharest (Romania): Wiley 10.1111/j.1582-4934.2009.00870.x

Mueller, Beatrice U; Pabst, Thomas (2010). Lineage-specific transcription factor aberrations in AML. Cancer treatment and research, 145, pp. 109-125. New York, N.Y.: Springer Science+Business Media

Bonadies, N; Neururer, Ch; Steege, A; Vallabhapurapu, S; Pabst, T; Mueller, B U (2010). PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer element. Oncogene, 29(7), pp. 1062-72. Basingstoke, UK: Nature Publishing Group 10.1038/onc.2009.371

Eich, Hans Theodor; Diehl, Volker; Görgen, Helen; Pabst, Thomas; Markova, Jana; Debus, Jürgen; Ho, Anthony; Dörken, Bernd; Rank, Andreas; Grosu, Anca-Ligia; Wiegel, Thomas; Karstens, Johann Hinrich; Greil, Richard; Willich, Normann; Schmidberger, Heinz; Döhner, Hartmut; Borchmann, Peter; Müller-Hermelink, Hans-Konrad; Müller, Rolf-Peter and Engert, Andreas (2010). Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of clinical oncology, 28(27), pp. 4199-206. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.29.8018

Eyholzer, M; Schmid, S; Wilkens, L; Mueller, B U; Pabst, T (2010). The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. British journal of cancer, 103(2), pp. 275-84. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6605751

Taverna, C; Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C (2010). Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss medical weekly, 140, w13054. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2010.13054

Löwenberg, Bob; Beck, Joachim; Graux, Carlos; van Putten, Wim; Schouten, Harry C; Verdonck, Leo F; Ferrant, Augustin; Sonneveld, Pieter; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; Breems, Dimitri; de Muijnck, Hilde; Schaafsma, Ron; Verhoef, Gregor; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Ossenkoppele, Gert J; ... (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), pp. 2586-91. Washington, D.C.: American Society of Hematology 10.1182/blood-2009-10-246470

Novy, Jan; Rosselet, Anne; Spertini, Olivier; Lobrinus, Johannes Alexander; Pabst, Thomas; Kuntzer, Thierry (2010). Chemotherapy is successful in sporadic late onset nemaline myopathy (SLONM) with monoclonal gammopathy. Muscle & nerve, 41(2), pp. 286-7. New York, N.Y.: John Wiley & Sons 10.1002/mus.21560

2009

Weininger, Markus; Lauterbach, Brigitte; Knop, Stefan; Pabst, Thomas; Kenn, Werner; Hahn, Dietbert; Beissert, Matthias (2009). Whole-body MRI of multiple myeloma: comparison of different MRI sequences in assessment of different growth patterns. European journal of radiology, 69(2), pp. 339-45. Stuttgart: Thieme 10.1016/j.ejrad.2007.10.025

Löwenberg, Bob; Ossenkoppele, Gert J; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Maertens, Johan; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; van Marwijk Kooy, Marinus; Verdonck, Leo F; Beck, Joachim; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Verhoef, Gregor (2009). High-dose daunorubicin in older patients with acute myeloid leukemia. New England journal of medicine NEJM, 361(13), pp. 1235-48. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa0901409

Pabst, Thomas; Mueller, Beatrice U (2009). Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clinical cancer research, 15(17), pp. 5303-7. Philadelphia, Pa.: Association for Cancer Research 10.1158/1078-0432.CCR-08-2941

Schardt, Julian A; Weber, Daniel; Eyholzer, Marianne; Mueller, Beatrice U; Pabst, Thomas (2009). Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clinical cancer research, 15(11), pp. 3834-41. Philadelphia, Pa.: Association for Cancer Research 10.1158/1078-0432.CCR-08-2870

Pabst, T; Eyholzer, M; Fos, J; Mueller, B U (2009). Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. British journal of cancer, 100(8), pp. 1343-6. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6604977

2008

Adès, Lionel; Sanz, Miguel A; Chevret, Sylvie; Montesinos, Pau; Chevallier, Patrice; Raffoux, Emmanuel; Vellenga, Edo; Guerci, Agnès; Pigneux, Arnaud; Huguet, Francoise; Rayon, Consuelo; Stoppa, Anne Marie; de la Serna, Javier; Cahn, Jean-Yves; Meyer-Monard, Sandrine; Pabst, Thomas; Thomas, Xavier; de Botton, Stéphane; Parody, Ricardo; Bergua, Juan; ... (2008). Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 111(3), pp. 1078-84. Washington, D.C.: American Society of Hematology 10.1182/blood-2007-07-099978

Pabst, Thomas; Eyholzer, Marianne; Haefliger, Simon; Schardt, Julian; Mueller, Beatrice U (2008). Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. Journal of clinical oncology, 26(31), pp. 5088-93. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2008.16.5563

Kirstetter, Peggy; Schuster, Mikkel B; Bereshchenko, Oksana; Moore, Susan; Dvinge, Heidi; Kurz, Elke; Theilgaard-Mönch, Kim; Månsson, Robert; Pedersen, Thomas A; Pabst, Thomas; Schrock, Evelin; Porse, Bo T; Jacobsen, Sten Eirik W; Bertone, Paul; Tenen, Daniel G; Nerlov, Claus (2008). Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer cell, 13(4), pp. 299-310. Cambridge, Mass.: Cell Press 10.1016/j.ccr.2008.02.008

2007

Pabst, T; Mueller, B U (2007). Transcriptional dysregulation during myeloid transformation in AML. Oncogene, 26(47), pp. 6829-37. Basingstoke, UK: Nature Publishing Group 10.1038/sj.onc.1210765

2006

Pabst, T; Fontana, S; Groebli, R; Leibundgut, K; Zwicky, C; Taleghani, BM (2006). Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiency. Transfusion, 46(8), pp. 1408-16. Malden, Mass.: Wiley-Blackwell 10.1111/j.1537-2995.2006.00910.x

Mueller, B U; Pabst, T; Hauser, P; Gilliland, G; Neuberg, D; Tenen, D G (2006). Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemia. British journal of cancer, 94(12), pp. 1918-20. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6603198

Pabst, Thomas; Stillner, Erica; Neuberg, Donna; Nimer, Stephen; Willman, Cheryl L; List, Alan F; Melo, Junia V; Tenen, Daniel G; Mueller, Beatrice U (2006). Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia. British journal of haematology, 133(4), pp. 400-2. Oxford: Wiley-Blackwell 10.1111/j.1365-2141.2006.06057.x

Mueller, Beatrice U; Pabst, Thomas (2006). Cutaneous zygomycosis at catheter insertion site in AML-M4Eo. Annals of hematology, 85(3), pp. 194-5. Berlin: Springer 10.1007/s00277-005-0053-5

Mueller, Beatrice U; Pabst, Thomas; Fos, José; Petkovic, Vibor; Fey, Martin F; Asou, Norio; Buergi, Ulrich; Tenen, Daniel G (2006). ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood, 107(8), pp. 3330-8. Washington, D.C.: American Society of Hematology 10.1182/blood-2005-07-3068

Mueller, Beatrice U; Pabst, Thomas (2006). C/EBPalpha and the pathophysiology of acute myeloid leukemia. Current opinion in hematology, 13(1), pp. 7-14. Hagerstown, Md.: Wolters Kluwer Lippincott Williams & Wilkins 10.1097/01.moh.0000190110.08156.96

Mueller, B U; Buerger, A U; Solenthaler, M; Garamvoelgyi, E M; Oppliger-Leibundgut, E; Fey, M F; Pabst, T (2006). Pleural tumors as sole primary manifestation of acute promyelocytic leukemia. Annals of oncology, 17(4), pp. 722-3. Oxford: Oxford University Press 10.1093/annonc/mdj062

Provide Feedback